PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis

Cellular Oncology

Volumn 34, Issue 6, 2011, Pages 523-531

  Sarasqueta, Arantza Farina ^a,e   Zeestraten, Eliane C M ^b   Van Wezel, Tom ^b   Van Lijnschoten, Gesina ^a   Van Eijk, Ronald ^b   Dekker, Jan Willem T ^b   Kuppen, Peter J K ^b   Goossens Beumer, Ines J ^b   Lemmens, Valery E P P ^c   Van De Velde, Cornelis J H ^b   Rutten, Harm J T ^d   Morreau, Hans ^b   Van Den Brule, A J C ^a,f  

^a Stichting Laboratoria voor Pathologie en Medische Microbiologie   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c The Netherlands   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

^e FONTYS UNIVERSITY OF APPLIED SCIENCES   (Netherlands)

^f JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

Biomarkers; Colon carcinoma; PIK3CA mutations; Prognostic factor

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT ALPHA; UNCLASSIFIED DRUG; PIK3CA PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; DISEASE FREE SURVIVAL; EXON; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; COLON TUMOR; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; YOUNG ADULT;

EID: 84859840481     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-011-0054-4     Document Type: Article

References (38)

1. C.G. Moertel, T.R. Fleming, J.S. Macdonald, D.G. Haller, J.A. Laurie, C.M. Tangen et al., Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med. 122(5), 321-326 (1995)
2. T. Andre, D. Sargent, J. Tabernero, M. O'Connell, M. Buyse, A. Sobrero et al., Current issues in adjuvant treatment of stage II colon cancer. Ann. Surg. Oncol. 13(6), 887-898 (2006) (Pubitemid 43727375)
3. C.B. Diep, L. Thorstensen, G.I. Meling, E. Skovlund, T.O. Rognum, R.A. Lothe, Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J. Clin. Oncol. 21(5), 820-829 (2003) (Pubitemid 46606441)
4. W.S. Jo, J.M. Carethers, Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark. 2(1-2), 51-60 (2006)
5. D.J. Sargent, S. Marsoni, G. Monges, S.N. Thibodeau, R. Labianca, S.R. Hamilton et al., Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 28(20), 3219-3226 (2010)
6. F.A. Sinicrope, R.L. Rego, N. Foster, D.J. Sargent, H.E. Windschitl, L.J. Burgart et al., Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am. J. Gastroenterol. 101(12), 2818-2825 (2006) (Pubitemid 44902656)
7. F.A. Sinicrope, R.L. Rego, K.C. Halling, N. Foster, D.J. Sargent, B. La Plant et al., Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 131(3), 729-737 (2006) (Pubitemid 44307064)
8. F.A. Sinicrope, D.J. Sargent, Clinical implications of microsatellite instability in sporadic colon cancers. Curr. Opin. Oncol. 21(4), 369-373 (2009)
9. A.D. Roth, S. Tejpar, M. Delorenzi, P. Yan, R. Fiocca, D. Klingbiel et al., Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 28 (3), 466-474 (2010)
10. A. Farina-Sarasqueta, G. van Lijnschoten, E. Moerland, G.J. Creemers, V.E. Lemmens, H.J. Rutten et al., The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann. Oncol. 21(12), 2396-2402 (2010)
11. K. Chen, P. Iribarren, W. Gong, J.M. Wang, The essential role of phosphoinositide 3-kinases (PI3Ks) in regulating pro-inflammatory responses and the progression of cancer. Cell. Mol. Immunol. 2(4), 241-252 (2005)
12. J.A. Engelman, J. Luo, L.C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7(8), 606-619 (2006) (Pubitemid 44100518)
13. L. Zhao, P.K. Vogt, Class I PI3K in oncogenic cellular transformation. Oncogene 27(41), 5486-5496 (2008)
14. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo et al., High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554 (2004) (Pubitemid 38541907)
15. A.G. Bader, S. Kang, P.K. Vogt, Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. U. S. A. 103(5), 1475-1479 (2006) (Pubitemid 43191190)
16. X.N. Guo, A. Rajput, R. Rose, J. Hauser, A. Beko, K. Kuropatwinski et al., Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. Canc. Res. 67(12), 5851-5858 (2007) (Pubitemid 46985019)
17. L. Barault, N. Veyrie, V. Jooste, D. Lecorre, C. Chapusot, J.M. Ferraz et al., Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int. J. Canc. 122(10), 2255-2259 (2008) (Pubitemid 351542328)
18. S. Ogino, K. Nosho, G.J. Kirkner, K. Shima, N. Irahara, S. Kure et al., PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J. Clin. Oncol. 27 (9), 1477-1484 (2009)
19. S. Velho, C. Moutinho, L. Cirnes, C. Albuquerque, R. Hamelin, F. Schmitt et al., BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Canc. 8, 255 (2008)
20. T. Ikenoue, F. Kanai, Y. Hikiba, T. Obata, Y. Tanaka, J. Imamura et al., Functional analysis of PIK3CA gene mutations in human colorectal cancer. Canc. Res. 65(11), 4562-4567 (2005) (Pubitemid 40740791)
21. C.H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V.E. Velculescu, K.W. Kinzler et al., The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318(5857), 1744-1748 (2007) (Pubitemid 350274378)
22. B. Markman, F. Atzori, J. Perez-Garcia, J. Tabernero, J. Baselga, Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann. Oncol. 21(4), 683-691 (2009)
23. M. Barbareschi, F. Buttitta, L. Felicioni, S. Cotrupi, F. Barassi, M. Del Grammastro et al., Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin. Canc. Res. 13(20), 6064-6069 (2007) (Pubitemid 350075063)
24. M. Miyaki, T. Iijima, T. Yamaguchi, K. Takahashi, H. Matsumoto, M. Yasutome et al., Mutations of the PIK3CA gene in hereditary colorectal cancers. Int. J. Canc. 121(7), 1627-1630 (2007) (Pubitemid 47328725)
25. S. Kato, S. Iida, T. Higuchi, T. Ishikawa, Y. Takagi, M. Yasuno et al., PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int. J. Canc. 121(8), 1771-1778 (2007) (Pubitemid 47417296)
26. H. Prenen, J. De Schutter, B. Jacobs, W. De Roock, B. Biesmans, B. Claes et al., PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Canc. Res. 15 (9), 3184-3188 (2009)
27. C.D. Hurst, T.C. Zuiverloon, C. Hafner, E.C. Zwarthoff, M.A. Knowles, A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res. Notes 2, 66 (2009)
28. C. Chaussade, K. Cho, C. Mawson, G.W. Rewcastle, P.R. Shepherd, Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochem. Biophys. Res. Commun. 381(4), 577-581 (2009)
29. Y.L. Lai, B.L. Mau, W.H. Cheng, H.M. Chen, H.H. Chiu, C.Y. Tzen, PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann. Surg. Oncol. 15 (4), 1064-1069 (2008)
30. H. Pang, R. Flinn, A. Patsialou, J. Wyckoff, E.T. Roussos, H. Wu et al., Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Canc. Res. 69(23), 8868-8876 (2009)
31. L. Zhao, P.K. Vogt, Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U. S. A. 105(7), 2652-2657 (2008) (Pubitemid 351520568)
32. N. Miled, Y. Yan, W.C. Hon, O. Perisic, M. Zvelebil, Y. Inbar et al., Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317(5835), 239-242 (2007) (Pubitemid 47076198)
33. V. Lemmens, L. van Steenbergen, M. Janssen-Heijnen, H. Martijn, H. Rutten, J.W. Coebergh, Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival. Acta Oncol. 49(6), 784-796 (2010)
34. L.N. van Steenbergen, M.A. Elferink, P. Krijnen, V.E. Lemmens, S. Siesling, H.J. Rutten et al., Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006. Ann. Oncol. 21(11), 2206-2212 (2010)
35. W. De Roock, B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas et al., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11(8), 753-762 (2010)
36. S.M. Johnson, P. Gulhati, B.A. Rampy, Y. Han, P.G. Rychahou, H. Q. Doan et al., Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J. Am. Coll. Surg. 210(5), 776-778 (2010)
37. H.C. Kwon, S.H. Kim, M.S. Roh, J.S. Kim, H.S. Lee, H.J. Choi et al., Gene expression profiling in lymph node-positive and lymph nodenegative colorectal cancer. Dis. Colon. Rectum 47(2), 141-152 (2004)
38. N.T. Ihle, G. Powis, Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol. Aspects Med. 31(2), 135-144 (2010)